Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: R688- Other general symptoms and signs
Conditions
Interventions
Intervention1: MYCOPHENOLATE SODIUM: Subjects with Covid 19 infection participating in the study will receive Mycophenolate Sodium for a period of 1 month from the diagnosis in addition to the standar
Sponsors
Shri Janai Research Foundation
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects with active COVID ââ?¬â?? 19 infection. 2. Age more than 18 years. 3. Actual or estimated weight more than 50kg. 4. Mild to moderate infection. 5. Subjects willing to give consent for participation in the study. 6. No clinical contraindications for Mycophenolate administration.
Exclusion criteria
Exclusion criteria: 1. Age less than 18 years. 2. Subjects not willing to give consent for participation in the study. 3. Subjects having pancytopenia. 4. Subjects with secondary bacterial sepsis. 5. Subjects already taking immunosuppressive medications for other conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of Mycophenolate on mortality due to COVID-19 infection.Timepoint: 30 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the effect of Mycophenolate on need of hospitalization, inflammatory markers, length of hospital stay, length of ICU stay and economic burden of the treatment of the COVID ââ?¬â?? 19 infection. To assess the safety of Mycophenolate when used in the treatment of COVID ââ?¬â?? 19 infection. Timepoint: 30 days | — |
Countries
India
Contacts
Public ContactDr Atul Sajgure
Sahyadri Speciality Hospital
Outcome results
None listed